2017 - 2018 LEGISLATURE
March 16, 2017 - Introduced by Representatives Sinicki, Bowen, E. Brooks,
Fields, Horlacher, Kolste, Milroy, Murphy, Ohnstad, C. Taylor,
Thiesfeldt and Wachs, cosponsored by Senators Darling, Cowles, Johnson,
C. Larson, Vinehout and Wirch. Referred to Committee on Rules.
AJR19,1,1 1Relating to: designating June 2017 as Myasthenia Gravis Awareness Month.
AJR19,1,42 Whereas, myasthenia gravis (MG) is an autoimmune neuromuscular disease
3that causes chronic weakness, in which antibodies attack receptors in the body and
4prevent muscle contraction; and
AJR19,1,85 Whereas, MG frequently weakens muscles that control eye movement, facial
6expressions, and swallowing, and its symptoms may include blurred vision, speech
7impairment, difficulty chewing, shortness of breath, an unstable gait, and a
8weakened grip; and
AJR19,1,109 Whereas, a diagnosis of MG may be missed or delayed because its symptoms
10are in common with many other disorders; and
AJR19,1,1411 Whereas, in some cases MG symptoms can worsen to the point of disability,
12grave illness, or death, if there are gaps in or an absence of the several crucial health
13care treatments that can enable those who endure MG to lead productive, active lives
14of normal longevity; and
1Whereas, MG is found most commonly in adult women under 40 and men over
260, but is not specific to either gender or any particular ethnic background; and
AJR19,2,33 Whereas, MG is nonhereditary and noncontagious; and
AJR19,2,54 Whereas, 10 to 20 out of every 100,000 Americans are diagnosed with MG, and
5for those people support groups exist in Wisconsin; now, therefore, be it
AJR19,2,7 6Resolved by the assembly, the senate concurring, That June 2017 is
7hereby designated Myasthenia Gravis Awareness Month in Wisconsin.
AJR19,2,88 (End)